Bruce Thornton - Sonoma Pharmaceuticals President
| SNOA Stock | USD 0.16 0.01 6.67% |
President
Mr. Bruce Thornton is Executive Vice President International Operations and Sales of the Company. He served as our General Manager for U.S. operations from March 2004 to July 2005. He served as Vice President of Operations for Jomed from January 1999 to September 2003, and as Vice President of Manufacturing for Volcano Therapeutics, an international medical device company, following its acquisition of Jomed, until March 2004. since 2008.
| Age | 60 |
| Tenure | 16 years |
| Professional Marks | MBA |
| Address | 5445 Conestoga Court, Boulder, CO, United States, 80301 |
| Phone | 800 759 9305 |
| Web | https://www.sonomapharma.com |
Bruce Thornton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bruce Thornton against Sonoma Pharmaceuticals stock is an integral part of due diligence when investing in Sonoma Pharmaceuticals. Bruce Thornton insider activity provides valuable insight into whether Sonoma Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Sonoma Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sonoma Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bruce Thornton over three months ago Acquisition by Bruce Thornton of 60000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Bruce Thornton over six months ago Acquisition by Bruce Thornton of 100000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 |
Sonoma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1944) % which means that it has lost $0.1944 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8287) %, meaning that it created substantial loss on money invested by shareholders. Sonoma Pharmaceuticals' management efficiency ratios could be used to measure how well Sonoma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.35. At present, Sonoma Pharmaceuticals' Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Total Assets are forecasted to decline to about 15.2 M.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Michael Landine | Alkermes Plc | 70 | |
| Payson Swaffield | Evotec SE ADR | 61 | |
| Adrian Hepner | Eagle Pharmaceuticals | 56 | |
| CTodd Nichols | Alkermes Plc | N/A | |
| Shane Cooke | Alkermes Plc | 54 | |
| Elliot Ehrich | Alkermes Plc | 57 | |
| David Gaffin | Alkermes Plc | 52 | |
| Craig Hopkinson | Alkermes Plc | 49 | |
| Mark Namchuk | Alkermes Plc | N/A | |
| Mark Stejbach | Alkermes Plc | 55 | |
| Rebecca Peterson | Alkermes Plc | 38 | |
| Gordon Pugh | Alkermes Plc | 57 | |
Management Performance
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.19 |
Sonoma Pharmaceuticals Leadership Team
Elected by the shareholders, the Sonoma Pharmaceuticals' board of directors comprises two types of representatives: Sonoma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sonoma. The board's role is to monitor Sonoma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sonoma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sonoma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Schutz, President CEO, Director | ||
| Robert Northey, Executive Vice President - Research and Development | ||
| Jerry McLaughlin, Lead Independent Director | ||
| Jerome Dvonch, Interim Officer | ||
| John Poggetto, Controller | ||
| Bruce Thornton, Executive Vice President - International Operations and Sales | ||
| Robert Miller, CFO, COO, Secretary | ||
| Russell Harrison, Independent Director | ||
| Marc Umscheid, Chief Strategy and Marketing Officer | ||
| Sharon Barbari, Independent Director | ||
| Victoria Covel, Assistant Controller | ||
| Chad White, Interim Officer | ||
| Frederick Sandford, CEO and Interim CFO | ||
| Philippe Weigerstorfer, Independent Director | ||
| Amy Trombly, President CEO | ||
| Dan McFadden, IR Contact Officer | ||
| Jay Birnbaum, Independent Director |
Sonoma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sonoma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 435.61 K | ||||
| Shares Outstanding | 15.61 M | ||||
| Shares Owned By Insiders | 1.55 % | ||||
| Shares Owned By Institutions | 1.95 % | ||||
| Number Of Shares Shorted | 30.35 K | ||||
| Price To Earning | 2.57 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sonoma Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sonoma Pharmaceuticals' short interest history, or implied volatility extrapolated from Sonoma Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Sonoma Stock analysis
When running Sonoma Pharmaceuticals' price analysis, check to measure Sonoma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sonoma Pharmaceuticals is operating at the current time. Most of Sonoma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Sonoma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sonoma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Sonoma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Sonoma Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.82) | Revenue Per Share 1.946 | Quarterly Revenue Growth 0.066 | Return On Assets (0.19) | Return On Equity (0.83) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.